172733-08-3

Upstream product

• 79-37-8 oxalyl dichloride 
• 172733-07-2 2-[[2-Ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester 
• 172733-06-1 1-benzyl-2-ethyl-1H-indol-4-ol 
• 948553-63-7 (1-Benzyl-3-chlorooxalyl-2-ethyl-1H-indol-4-yloxy)-acetic acid methyl ester 
• 164082-80-8 1-benzyl-2-ethyl-4-methoxy-1H-indole 

Downstream Products

• 172732-68-2 ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid 
• 172733-42-5 sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate 
• 331440-80-3 2-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl] oxy]-N-(hydroxy)acetamide 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM 3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE

A lyophilized pharmaceutical composition is described which contains Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]acetate, a Solubilizer, and a Stabilizer. Such compositions are storage stable and readily dissolve in aqueous medium to give injectable solution for treatment of sepsis, etc.

Novel sPLA2 inhibitors

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

Novel sPLA2 inhibitors

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

Indole sPLA2 inhibitors

A class of novel acylsulfonamide substituted indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2mediated release of fatty acids for treatment of inflammatory diseases.

Combination therapy for the treatment of inflammatory and respiratory diseases

A pharmaceutical composition for the treatment of Inflammatory Disease or Respiratory Disease in mammals, which comprises, as active ingredients, a neutrophil elastase inhibitor and an sPLA2 inhibitor.

SPLA2 inhibitor compounds for treatment of disease

The present invention is directed to compounds for treating inflammatory bowel disease. More specifically, the present invention is directed to 1H-indole-3-glyoxyamide compounds a sPLA2inhibitors for treating inflammatory bowel disease.

Method for the treatment of stroke using N-heterocyclic glyoxlyamide compounds

A method and composition for the treatment and/or prevention of stroke is disclosed using N-heterocyclic glyoxamide compounds having the following general formula: wherein X, E, F, R11, R12, R14, R15, R16and R17are as defined herein.

Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor

The compound, ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid morpholino-N-ethyl ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA2 mediated release of fatty acids fo

Method for treatment of chronic bronchitis using indole compounds

A method is disclosed for the treatment of chronic bronchitis by administering to a mammal in need thereof a therapeutically effective amount of a 1H-indole-3-glyoxylamide compound.

1H-INDOLE-3-GLYOXYLAMIDE SPLA2 INHIBITORS

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty adds for treatment of conditions such as septic shock